Consumer products group Reckitt Benckiser posted a trading update for its first quarter on Friday, reporting it was in line with expectations with continued strong performance in the health division led by Mucinex and Durex.
The FTSE 100 firm said that growth was offset by headwind in Scholl / Amopé, which also impacted Europe-North America performance.
Growth rates were set to improve through the year, and RB said it was on track for its full year net revenue target of 3% like-for-like.
